Results 311 to 320 of about 416,036 (340)
Some of the next articles are maybe not open access.
American Journal of Kidney Diseases, 1986
Cis-dichlorodiammine platinum (II), or cisplatin, has emerged as a principal chemotherapeutic agent in the treatment of otherwise resistant solid tumors and is currently among the most widely used agents in the chemotherapy of cancer. The chief limit to its greater efficacy is its nephrotoxicity, which has made it necessary both to lower its dosage and
R, Safirstein +5 more
openaire +2 more sources
Cis-dichlorodiammine platinum (II), or cisplatin, has emerged as a principal chemotherapeutic agent in the treatment of otherwise resistant solid tumors and is currently among the most widely used agents in the chemotherapy of cancer. The chief limit to its greater efficacy is its nephrotoxicity, which has made it necessary both to lower its dosage and
R, Safirstein +5 more
openaire +2 more sources
Journal of Proteomics, 2012
Cisplatin is a major broad-spectrum chemotherapeutic agent, however, its dose-dependent side effects limit the administration of large doses. Presently, developing a drug targeted delivery system is suggested as one of the most promising approaches to minimize the side effects of cisplatin. Here, we found that each human serum transferrin (HTf) has the
Luo, Lian-Zhong +2 more
openaire +4 more sources
Cisplatin is a major broad-spectrum chemotherapeutic agent, however, its dose-dependent side effects limit the administration of large doses. Presently, developing a drug targeted delivery system is suggested as one of the most promising approaches to minimize the side effects of cisplatin. Here, we found that each human serum transferrin (HTf) has the
Luo, Lian-Zhong +2 more
openaire +4 more sources
The nephrotoxicity of cisplatin
Life Sciences, 1983Cisplatin is a cancer chemotherapeutic agent whose clinical use is complicated by its dose related kidney toxicity. Since the histopathological profile of cisplatin nephrotoxicity appears similar to that of other heavy metals, it has been commonly presumed that cisplatin nephrotoxicity is related to the platinum moiety. However, the delayed time course
Robin S. Goldstein, Gilbert H. Mayor
openaire +2 more sources
2021
Platinum-based agents belong to alkylating antineoplastic agents. They are the backbone of most chemotherapeutic regimens in many cancer types, including testicular cancer, ovarian cancer, cervical cancer, breast cancer, lung cancer, bladder cancer, and head and neck cancer.
Michelle N. Johnson, Lili Zhang
openaire +2 more sources
Platinum-based agents belong to alkylating antineoplastic agents. They are the backbone of most chemotherapeutic regimens in many cancer types, including testicular cancer, ovarian cancer, cervical cancer, breast cancer, lung cancer, bladder cancer, and head and neck cancer.
Michelle N. Johnson, Lili Zhang
openaire +2 more sources
Cisplatin Nephrotoxicity: A Review [PDF]
The American Journal of the Medical Sciences, 2007 Cisplatin is a major antineoplastic drug for the treatment of solid tumors, but it has dose-dependent renal toxicity.We reviewed clinical and experimental literature on cisplatin nephrotoxicity to identify new information on the mechanism of injury and potential approaches to prevention and/or treatment.Unbound cisplatin is freely filtered at the ...
Xin Yao +3 more
openaire +2 more sources
Adriamycin and cisplatin for hepatoblastoma
Cancer, 1985Four consecutive infants and children with hepatoblastomas were treated with a combination of Adriamycin (doxorubicin) and cisplatin. Three patients had unresectable tumors and in each there was a dramatic decrease in tumor size and serum alpha-fetoprotein (AFP) levels.
Ronald W. Cooke +5 more
openaire +3 more sources
New England Journal of Medicine, 1980
CISPLATIN (cis-diamminedichloroplatinum) has been tested extensively against various solid tumors and has become commercially available.
J Fitzpatrick +3 more
openaire +3 more sources
CISPLATIN (cis-diamminedichloroplatinum) has been tested extensively against various solid tumors and has become commercially available.
J Fitzpatrick +3 more
openaire +3 more sources
Neurotoxicity of cisplatin and taxol
International Journal of Gynecological Cancer, 1995Since the discovery of the activity of cisplatin in ovarian cancer approximately 15 years ago, there has been little progress in improving survival for patients with this disease. Thus there has been great enthusiasm in the gynecologic oncology community over the results of GOG111, the Gynecologic Oncology Group (GOG) study randomizing suboptimally ...
openaire +3 more sources
Is Cisplatin a Human Carcinogen?
JNCI Journal of the National Cancer Institute, 1992Traditionally, cisplatin has not been regarded among chemotherapeutic drugs as a carcinogenic risk to humans because it is not a classical alkylating agent. A review of recently published experimental data indicates that cisplatin is mutagenic, clastogenic, capable of inducing cell transformation, able to act as an initiator in classical mouse skin ...
openaire +3 more sources
Mechanisms of resistance to cisplatin [PDF]
, 1991 A number of changes have been detected in cisplatin-resistant cells, some of which are likely to be directly involved in the mechanism of resistance. The four most cited mechanisms are reduced accumulation, increased glutathione, increased metallothionein, and enhanced DNA repair.
openaire +2 more sources